Enliven Therapeutics (ELVN) Total Non-Current Liabilities (2022 - 2025)

Enliven Therapeutics has disclosed Total Non-Current Liabilities across 4 years of filings, most recently posting $14.6 million for Q3 2025.

• Total Non-Current Liabilities for Q3 2025 came in at $14.6 million, down 13.96% year-over-year; the trailing twelve-month figure through Sep 2025 was $14.6 million (down 13.96% YoY), and the FY2024 annual result was $15.9 million, down 38.54% from the prior year.
• Total Non-Current Liabilities came in at $14.6 million for Q3 2025 at Enliven Therapeutics, down from $15.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $25.9 million in Q4 2023 to a low of $9.1 million in Q2 2023.
• The 4-year median for Total Non-Current Liabilities is $14.9 million (2025), against an average of $16.0 million.
• Across the five-year window, Total Non-Current Liabilities surged 166.54% in 2023 and slumped 44.18% in 2025, its largest moves.
• Enliven Therapeutics' Total Non-Current Liabilities stood at $9.7 million in 2022, then soared by 166.54% to $25.9 million in 2023, then tumbled by 38.54% to $15.9 million in 2024, then dropped by 7.95% to $14.6 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $14.6 million (Q3 2025), $15.2 million (Q2 2025), and $14.0 million (Q1 2025), per Business Quant data.